{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:15:41Z","timestamp":1788156941861,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) represents a significant health problem worldwide with high morbidity, mortality, and development of end-stage kidney disease (ESKD). Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent an innovative class of medications with possible cardiorenal advantages. We conducted a Meta-analysis to assess their efficacy in CKD management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our Meta-analysis was performed using the Preferred Reporting Items for Meta-analyses (PRISMA) guidelines and is registered in PROSPERO (CRD420261362785). Databases used for conducting this systematic review include Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, PubMed Central, and Google Scholar. The databases were searched from their inception till 16 April 2026. Clinical trials in adults diagnosed with CKD were included in this study if they compared the use of SGLT2 inhibitors versus placebo. A random-effects model was used for meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirteen randomized controlled trials (RCTs) (n = 49,931) were analyzed. A statistically significant increase in total and chronic estimated glomerular filtration rate (eGFR) slope was seen (mean difference: MD = 0.97\u00a0mL\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      \/year, 95% CI: 0.34 to 1.59 and MD = 1.92, 95% CI: 1.91\u20131.93). There was a statistically significant reduction in albuminuria (ratio of means showing 37% reduction, 95% CI: 1.12\u20131.68). The risk of ESKD was significantly reduced by 30% (RR = 0.70, 95% CI: 0.65\u20130.75), while the doubling of serum creatinine risk was diminished by 33% (RR = 0.67, 95% CI: 0.56\u20130.79). SGLT2 inhibitors also lowered the risk of all-cause mortality (RR = 0.80, 95% CI: 0.68\u20130.93), cardiovascular mortality (RR = 0.79, 95% CI: 0.65\u20130.95), and heart failure-related hospitalization (RR = 0.74, 95% CI: 0.67\u20130.82). The number of serious adverse events decreased (RR = 0.92, 95% CI: 0.88\u20130.95), while overall adverse events remained unchanged (RR = 0.99, 95% CI: 0.96\u20131.02). However, there was evidence of higher risk of developing diabetic ketoacidosis (RR = 2.06, 95% CI: 1.19\u20133.58) and volume depletion (RR = 1.28, 95% CI: 1.13\u20131.45).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2 inhibitors were effective in delaying the progression of CKD and lowering mortality. However, despite having a relatively safe profile, this drug class comes with certain hazards that need to be monitored clinically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420261362785.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1923548","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:40:10Z","timestamp":1788154810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Arjun","family":"Sharma","sequence":"first","affiliation":[{"name":"Harvard Medical School, Harvard University","place":["Boston, MA, United States"]},{"name":"Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Sharma","sequence":"additional","affiliation":[{"name":"Gori Devi Girls College, University of Rajasthan","place":["Jaipur, Rajasthan, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepthi Sree","family":"Vamaraju","sequence":"additional","affiliation":[{"name":"Institute of Systems Science, National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrendra Kumar","family":"Ajay","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University","place":["Boston, MA, United States"]},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of Canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e2924","DOI":"10.1002\/dmrr.2924","article-title":"Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data","volume":"33","author":"Blau","year":"2017","journal-title":"Diabetes Metab. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"154937","DOI":"10.1016\/j.metabol.2021.154937","article-title":"SGLT-2 inhibitors as cardio-renal protective agents","volume":"127","author":"Caruso","year":"2022","journal-title":"Metabolism"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/jcs8050172","article-title":"Quality of life of dialysis patients: exploring the influence of membrane hemocompatibility and dialysis practices on psychosocial and physical symptoms","volume":"8","author":"Doan","year":"2024","journal-title":"J. Compos Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/s12933-025-03009-8","article-title":"Joint association of urinary albumin-to-creatinine ratio within normal range and triglyceride-glucose index with incident cardiovascular disease: a prospective cohort study","volume":"24","author":"Fengjun","year":"2025","journal-title":"Cardiovasc Diabetol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1002\/ehf2.15393","article-title":"Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: insights from EMPACT-MI","volume":"12","author":"Fioretti","year":"2025","journal-title":"ESC Heart Fail."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/sim.4501","article-title":"Ratio of geometric means to analyze continuous outcomes in meta-analysis: comparison to mean differences and ratio of arithmetic means using empiric data and simulation","volume":"31","author":"Friedrich","year":"2012","journal-title":"Statistics Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamacardio.2025.4581","article-title":"Chronic kidney disease prevalence and awareness among US adults","volume":"11","author":"Gong","year":"2026","journal-title":"JAMA Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2215\/CJN.14231021","article-title":"Dapagliflozin and kidney outcomes in hospitalized patients with COVID-19 infection: an analysis of the DARE-19 randomized controlled trial","volume":"17","author":"Heerspink","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis","volume":"21","author":"Kaze","year":"2022","journal-title":"Cardiovasc Diabetol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40620-020-00803-3","article-title":"Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations","volume":"33","author":"Leoncini","year":"2020","journal-title":"J. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2215\/CJN.14901219","article-title":"Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial","volume":"15","author":"Levin","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the global burden of disease study 2023","volume":"406","author":"Mark","year":"2025","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Syst. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12325-021-01994-2","article-title":"Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape","volume":"39","author":"Mende","year":"2022","journal-title":"Adv. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1002983","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.ajkd.2021.09.029","article-title":"Diuretics in states of volume overload: Core curriculum 2022","volume":"80","author":"Novak","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.3390\/ijms22115863","article-title":"Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects","volume":"22","author":"Palmiero","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B28","unstructured":"RStudio: integrated development environment for R\n          \n          \n          2025"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"IJMS"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-preserved trial","volume":"25","author":"Sharma","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"B31","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s10157-010-0365-1","article-title":"Doubling of serum creatinine: is it appropriate as the endpoint for CKD? Proposal of a new surrogate endpoint based on the reciprocal of serum creatinine","volume":"15","author":"Takeuchi","year":"2011","journal-title":"Clin. Exp. Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/ndt\/gfaf197","article-title":"Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index","volume":"41","author":"Vargas-Brochero","year":"2026","journal-title":"Nephrol. Dial. Transplant."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1111\/jdi.13888","article-title":"Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan","volume":"13","author":"Wada","year":"2022","journal-title":"J. Diabetes Invest."},{"key":"B37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1574693","DOI":"10.3389\/fmed.2025.1574693","article-title":"Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety","volume":"12","author":"Zhang","year":"2025","journal-title":"Front. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11906-017-0771-9","article-title":"Effects of RAAS inhibitors in patients with kidney disease","volume":"19","author":"Zhang","year":"2017","journal-title":"Curr. Hypertens. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","article-title":"Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association","volume":"119","author":"Zoccali","year":"2023","journal-title":"Cardiovasc. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1923548\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:40:11Z","timestamp":1788154811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1923548\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":41,"alternative-id":["10.3389\/fphar.2026.1923548"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1923548","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1923548"}}